W F Hahne
Overview
Explore the profile of W F Hahne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gardner J, Perdomo C, Sloan S, Hahne W, Barth J, Rodriguez-Stanley S, et al.
Aliment Pharmacol Ther
. 2002 Mar;
16(3):455-64.
PMID: 11876698
Background: Integrated gastric and oesophageal acidity can be calculated from measurements of gastric and oesophageal pH and used to quantify gastric and oesophageal acidity over time. Rabeprazole is a new...
2.
Philip B, Pearman M, Kovac A, Chelly J, WETCHLER B, McKenzie R, et al.
Eur J Anaesthesiol
. 2000 Apr;
17(1):23-32.
PMID: 10758440
In a multicentre, randomized, double-blind, placebo-controlled dose-ranging study, 1030 patients undergoing outpatient surgery with general anaesthesia received i.v. dolasetron mesylate (12.5, 25, 50, or 100 mg) or placebo. The principal...
3.
Lippert C, Dimmitt D, Martin L, Cramer M, Plezia P, Hahne W
Am J Ther
. 1999 Jul;
6(3):129-35.
PMID: 10423655
Dolasetron mesylate (MDL 73,147, Anzemet, Hoechst Marion Roussel, Kansas City, MO) is a 5-HT ( 3 ) receptor antagonist undergoing clinical evaluation as an antiemetic agent. Dolasetron is rapidly metabolized...
4.
Dimmitt D, Choo Y, Martin L, Arumugham T, Hahne W, Weir S
Biopharm Drug Dispos
. 1999 Mar;
20(1):41-8.
PMID: 10086836
The single- and multiple-dose pharmacokinetics and dose-proportionality of oral dolasetron and its active metabolites over the therapeutic dose range was investigated in 18 healthy men. In an open-label, randomized, complete...
5.
Dimmitt D, Choo Y, Martin L, Arumugham T, Hahne W, Weir S
Biopharm Drug Dispos
. 1999 Mar;
20(1):29-39.
PMID: 10086835
In this first part of a two-part investigation, the intravenous dose proportionality of dolasetron mesylate, a 5-HT3 receptor antagonist, and the absolute bioavailability of oral dolasetron mesylate were investigated. In...
6.
Whitmore J, Kris M, Hesketh P, Grote T, DUBOIS D, Cramer M, et al.
Support Care Cancer
. 1998 Oct;
6(5):473-8.
PMID: 9773466
Dolasetron mesilate is a selective 5-HT3 receptor antagonist that prevents chemotherapy-induced and postoperative nausea and vomiting. For the majority of patients in intravenous dolasetron trials for chemotherapy-induced nausea and vomiting,...
7.
Diemunsch P, KORTTILA K, Leeser J, Helmers J, Wilkey B, Nave S, et al.
J Clin Anesth
. 1998 Apr;
10(2):145-52.
PMID: 9524901
Study Objective: To examine the safety and effectiveness of a range of single oral doses of dolasetron mesylate for the prevention of postoperative nausea and vomiting. Design: Randomized, double-blind, placebo-controlled...
8.
Stubbs K, Martin L, Dimmitt D, Pready N, Hahne W
J Clin Pharmacol
. 1998 Mar;
37(10):926-36.
PMID: 9505984
In previous studies, dolasetron was shown to have both renal and hepatic elimination mechanisms. This study was conducted to determine the impact of varying degrees of hepatic dysfunction on the...
9.
Kovac A, Scuderi P, Boerner T, Chelly J, Goldberg M, Hantler C, et al.
Anesth Analg
. 1997 Sep;
85(3):546-52.
PMID: 9296407
Unlabelled: This study was conducted to determine the efficacy and safety of four intravenous (I.V.) doses of dolasetron, an investigational 5-HT3 receptor antagonist, for the treatment of postoperative nausea and/or...
10.
Diemunsch P, Dhollander A, Paxton L, Schoeffler P, Wessel P, Nave S, et al.
J Clin Anesth
. 1997 Aug;
9(5):365-73.
PMID: 9257201
Study Objective: To evaluate a range of doses of intravenous (i.v.) dolasetron mesilate, in preventing postoperative nausea and vomiting (PONV). Design: Double-blind, placebo-controlled, randomized, multicenter trial. Setting: Ten hospitals and/or...